MCID: PRT096
MIFTS: 54

Peritoneal Mesothelioma

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Peritoneal Mesothelioma

MalaCards integrated aliases for Peritoneal Mesothelioma:

Name: Peritoneal Mesothelioma 12 14 69
Malignant Mesothelioma of Peritoneum 12 69
Advanced Malignant Mesothelioma of Peritoneum 12
Advanced Malignant Peritoneal Mesothelioma 12
Advanced Peritoneal Malignant Mesothelioma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1788
ICD10 32 C45.1
NCIt 46 C8704 C9350
SNOMED-CT 64 109853004 187806007

Summaries for Peritoneal Mesothelioma

Disease Ontology : 12 A peritoneum cancer that develops from cells of the mesothelium and is located in the peritoneum.

MalaCards based summary : Peritoneal Mesothelioma, also known as malignant mesothelioma of peritoneum, is related to malignant peritoneal mesothelioma and mucinous adenocarcinoma, and has symptoms including abdominal pain An important gene associated with Peritoneal Mesothelioma is WT1 (Wilms Tumor 1), and among its related pathways/superpathways are Pathways in cancer and Proteoglycans in cancer. The drugs Doxorubicin and Doxil have been mentioned in the context of this disorder. Affiliated tissues include the peritoneum, colon and t cells, and related phenotypes are Decreased cell migration and Decreased viability after Chlamydia trachomatis serovar L2 infection and TNF-alpha/CHX stimulation

Wikipedia : 72 Peritoneal mesothelioma is the name given to the cancer that attacks the lining of the abdomen. This... more...

Related Diseases for Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 226)
# Related Disease Score Top Affiliating Genes
1 malignant peritoneal mesothelioma 33.5 CDKN2A EGFR MUC1 NF2
2 mucinous adenocarcinoma 29.9 CDKN2A EGFR MUC1
3 adenocarcinoma 29.8 CDKN2A EGFR MET MUC1
4 papillary carcinoma 29.7 MET MUC1 PGR
5 malignant peripheral nerve sheath tumor 29.5 CDKN2A EGFR MUC1 NF2
6 renal cell carcinoma, nonpapillary 29.0 EGFR MET MUC1 WT1
7 ovarian cancer 29.0 EGFR ESR1 MET MUC1 PGR
8 ovarian cancer 1 28.8 EGFR ESR1 MUC1 PGR WT1
9 benign multicystic peritoneal mesothelioma 12.5
10 benign peritoneal mesothelioma 12.3
11 peritoneal cystic mesothelioma 11.1
12 peritonitis 11.0
13 lymphohistiocytoid mesothelioma 10.5 CDKN2A THBD
14 hepatoid adenocarcinoma 10.5 EGFR MUC1
15 anaplastic oligodendroglioma 10.5 CDKN2A EGFR
16 squamous cell carcinoma of the larynx 10.5 CDKN2A EGFR
17 gastric adenosquamous carcinoma 10.5 CDKN2A EGFR
18 mucinous bronchioloalveolar adenocarcinoma 10.4 CDKN2A MUC1
19 cholangiolocellular carcinoma 10.4 CDKN2A MUC1
20 transitional meningioma 10.4 MUC1 NF2
21 pleomorphic liposarcoma 10.4 CDKN2A MUC1
22 fibrous meningioma 10.4 MUC1 NF2
23 cervical adenosquamous carcinoma 10.4 CDKN2A EGFR
24 ischemic fasciitis 10.4 CDKN2A MUC1
25 plasmablastic lymphoma 10.4 CDKN2A MUC1
26 well-differentiated liposarcoma 10.4 CDKN2A MUC1
27 optic nerve sheath meningioma 10.4 CDKN2A NF2
28 anaplastic ependymoma 10.4 MUC1 NF2
29 oropharynx cancer 10.4 CDKN2A EGFR
30 atypical neurofibroma 10.4 CDKN2A NF2
31 meningeal melanocytoma 10.4 CDKN2A MUC1
32 syringoma 10.4 ESR1 MUC1
33 basaloid squamous cell carcinoma 10.4 CDKN2A EGFR
34 intracystic papillary adenoma 10.4 EGFR PGR
35 progesterone-receptor negative breast cancer 10.4 EGFR PGR
36 endocervical carcinoma 10.3 CDKN2A ESR1
37 breast mucoepidermoid carcinoma 10.3 MUC1 PGR
38 breast squamous cell carcinoma 10.3 EGFR PGR
39 biliary tract neoplasm 10.3 CDKN2A MUC1
40 malignant mixed mullerian tumor 10.3 MUC1 PGR
41 clear cell meningioma 10.3 MUC1 PGR
42 doxorubicin induced cardiomyopathy 10.3 EGFR MET
43 vulvar dystrophy 10.3 CDKN2A PGR
44 bizarre leiomyoma 10.3 CDKN2A PGR
45 lobular neoplasia 10.3 ESR1 MUC1
46 small cell sarcoma 10.3 CDKN2A NF2
47 microglandular adenosis 10.3 EGFR PGR
48 lung meningioma 10.3 NF2 PGR
49 perivascular epithelioid cell tumor 10.3 MUC1 PGR
50 acral lentiginous melanoma 10.3 CDKN2A MET

Graphical network of the top 20 diseases related to Peritoneal Mesothelioma:



Diseases related to Peritoneal Mesothelioma

Symptoms & Phenotypes for Peritoneal Mesothelioma

UMLS symptoms related to Peritoneal Mesothelioma:


abdominal pain

GenomeRNAi Phenotypes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.26 EGFR MET MUC1 NF2
2 Decreased viability after Chlamydia trachomatis serovar L2 infection and TNF-alpha/CHX stimulation GR00206-A 8.62 BIRC3 MET

MGI Mouse Phenotypes related to Peritoneal Mesothelioma:

43 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.17 THBD EGFR BIRC3 PGR CDKN2A MET
2 cellular MP:0005384 10.16 ESR1 THBD BIRC3 EGFR PGR CDKN2A
3 homeostasis/metabolism MP:0005376 10.16 THBD NF2 EGFR BIRC3 PGR CDKN2A
4 embryo MP:0005380 10.15 NF2 WT1 PGR CDKN2A MET ESR1
5 immune system MP:0005387 10.15 EGFR NF2 BIRC3 PGR CDKN2A MET
6 mortality/aging MP:0010768 10.09 THBD NF2 BIRC3 EGFR PGR CDKN2A
7 endocrine/exocrine gland MP:0005379 10.08 ESR1 NF2 EGFR PGR CDKN2A MET
8 hematopoietic system MP:0005397 10.07 THBD BIRC3 ESR1 EGFR PGR CDKN2A
9 liver/biliary system MP:0005370 10 EGFR NF2 WT1 CDKN2A MET ESR1
10 integument MP:0010771 9.95 ESR1 THBD NF2 EGFR PGR CDKN2A
11 muscle MP:0005369 9.95 EGFR BIRC3 PGR CDKN2A MET ESR1
12 neoplasm MP:0002006 9.91 NF2 WT1 PGR CDKN2A MET ESR1
13 no phenotypic analysis MP:0003012 9.8 EGFR PGR CDKN2A MET ESR1 WT1
14 normal MP:0002873 9.8 THBD EGFR BIRC3 PGR MET ESR1
15 renal/urinary system MP:0005367 9.63 THBD NF2 EGFR MET ESR1 WT1
16 reproductive system MP:0005389 9.5 THBD NF2 EGFR PGR CDKN2A ESR1
17 respiratory system MP:0005388 9.17 EGFR NF2 CDKN2A MET ESR1 THBD

Drugs & Therapeutics for Peritoneal Mesothelioma

Drugs for Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Doxil Approved June 1999 Phase 3,Phase 2 31703
3 Ranpirnase Investigational Phase 3 196488-72-9
4 Anti-Bacterial Agents Phase 3,Phase 2
5 Antibiotics, Antitubercular Phase 3,Phase 2
6 Topoisomerase Inhibitors Phase 3,Phase 2
7
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
8
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
9
Gemcitabine Approved Phase 2 95058-81-4 60750
10
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
11
Pemetrexed Approved, Investigational Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
12
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
13
Fluorouracil Approved Phase 2 51-21-8 3385
14
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 657311 5754
15
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
16
Pancrelipase Approved, Investigational Phase 2 53608-75-6
17
Promethazine Approved, Investigational Phase 2 60-87-7 4927
18
Ranitidine Approved Phase 2 66357-59-3, 66357-35-5 3001055
19
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
20
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
21
Pembrolizumab Approved Phase 2 1374853-91-4
22
Bevacizumab Approved, Investigational Phase 2 216974-75-3
23
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
24
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
25
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 439693 40926
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
27
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
28
Glutamic Acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
29
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
30 Anti-Infective Agents Phase 2,Phase 1
31 Antimetabolites Phase 2
32 Antimetabolites, Antineoplastic Phase 2
33 Antiviral Agents Phase 2,Phase 1
34 Immunosuppressive Agents Phase 2,Phase 1
35 Alkylating Agents Phase 2,Phase 1
36 Interferon-gamma Phase 2
37 interferons Phase 2,Phase 1
38 Mitomycins Phase 2
39 Nucleic Acid Synthesis Inhibitors Phase 2,Phase 1
40 Antibodies Phase 2,Phase 1
41 Antibodies, Monoclonal Phase 2,Phase 1
42 Immunoglobulins Phase 2,Phase 1
43
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
44 Protein Kinase Inhibitors Phase 2,Phase 1
45 Folic Acid Antagonists Phase 2,Phase 1
46 Vitamin B Complex Phase 2,Phase 1
47 Albumin-Bound Paclitaxel Phase 2,Phase 1
48 Antimitotic Agents Phase 2,Phase 1
49 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
50 Cortisol succinate Phase 2

Interventional clinical trials:

(show all 31)

# Name Status NCT ID Phase Drugs
1 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
2 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
3 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
4 Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
5 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
6 Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Completed NCT01592383 Phase 2 erlotinib hydrochloride
7 Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma Completed NCT00061477 Phase 2 Pemetrexed;Gemcitabine
8 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
9 αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies Recruiting NCT02151448 Phase 1, Phase 2 Celecoxib;Interferon Alfa-2b
10 Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study Recruiting NCT02588781 Phase 2 Pemetrexed
11 Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin Recruiting NCT02535312 Phase 1, Phase 2 Cisplatin;Methoxyamine;Pemetrexed Disodium
12 Pembrolizumab in Treating Patients With Malignant Mesothelioma Recruiting NCT02399371 Phase 2
13 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma Active, not recruiting NCT01843374 Phase 2 Tremelimumab;Placebo
14 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Active, not recruiting NCT01160458 Phase 2 IMC-A12
15 Atezolizumab and Bevacizumab in Rare Solid Tumors Active, not recruiting NCT03074513 Phase 2 Atezolizumab;Bevacizumab
16 SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Active, not recruiting NCT01362790 Phase 1, Phase 2 Pentostatin;Cyclophosphamide
17 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Enrolling by invitation NCT02040142 Phase 2
18 Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma Completed NCT02141347 Phase 1 Tremelimumab;MEDI4736
19 Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma Completed NCT00402766 Phase 1 Cisplatin;Imatinib Mesylate;Pemetrexed;Dexamethasone
20 Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma Recruiting NCT03436732 Phase 1 LMB-100;SEL-110
21 Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma Recruiting NCT02798536 Phase 1 LMB-100;nab-paclitaxel
22 Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Active, not recruiting NCT02029690 Phase 1 ADI-PEG 20
23 Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors. Active, not recruiting NCT01439152 Phase 1 BAY94-9343;BAY94-9343 (Expansion);BAY94-9343 (1.8 mg/kg);BAY94-9343 (2.2 mg/kg)
24 CAR T Cells in Mesothelin Expressing Cancers Active, not recruiting NCT03054298 Phase 1
25 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays Completed NCT02834234
26 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Completed NCT01812148
27 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Sur Recruiting NCT01416714
28 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed Recruiting NCT01617382
29 An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Recruiting NCT02754115
30 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting NCT01950572
31 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169

Search NIH Clinical Center for Peritoneal Mesothelioma

Genetic Tests for Peritoneal Mesothelioma

Anatomical Context for Peritoneal Mesothelioma

The Foundational Model of Anatomy Ontology organs/tissues related to Peritoneal Mesothelioma:

18
The Peritoneum

MalaCards organs/tissues related to Peritoneal Mesothelioma:

38
Colon, T Cells, Lung, Pancreas, Lymph Node, Ovary, Testis

Publications for Peritoneal Mesothelioma

Articles related to Peritoneal Mesothelioma:

(show top 50) (show all 388)
# Title Authors Year
1
Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. ( 29260418 )
2018
2
Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. ( 29431036 )
2018
3
Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases. ( 29048219 )
2018
4
Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma. ( 29423664 )
2018
5
Benign multicystic peritoneal mesothelioma treated with laparoendoscopic single site surgery: a case report and review of the literature. ( 29372166 )
2018
6
Significant Clinical Benefit of Pemetrexed-based Chemotherapy for Advanced Diffuse Malignant Peritoneal Mesothelioma: A Case Presentation. ( 28469343 )
2017
7
Presentation of a malignant peritoneal mesothelioma in the forma of rough hepatic calcifications. ( 28480727 )
2017
8
Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. ( 28189456 )
2017
9
The diagnostic utility of PAX8 immunostaining of malignant peritoneal mesothelioma presenting as serous ovarian carcinoma: A single-center report of two cases. ( 28123552 )
2017
10
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. ( 28910456 )
2017
11
Multicystic peritoneal mesothelioma: A short review. ( 28528021 )
2017
12
Benign Multicystic Peritoneal Mesothelioma: A Rare Condition in an Uncommon Gender. ( 28607791 )
2017
13
Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. ( 28100259 )
2017
14
Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. ( 28761723 )
2017
15
Malignant peritoneal mesothelioma, clear cell variant, in a female and its differentiation from clear cell carcinoma. ( 28215643 )
2017
16
Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. ( 28324285 )
2017
17
Reproducibility for histologic parameters in peritoneal mesothelioma. ( 28712777 )
2017
18
Epidemiology of malignant peritoneal mesothelioma: A population-based study. ( 29080447 )
2017
19
Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. ( 29184697 )
2017
20
Erratum: A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. ( 29267565 )
2017
21
Malignant peritoneal mesothelioma - a rare cause of laparotomy. ( 28702106 )
2017
22
Malignant peritoneal mesothelioma: a review. ( 28706904 )
2017
23
A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. ( 29019584 )
2017
24
Remote Recurrence of Benign Multicystic Peritoneal Mesothelioma. ( 28733062 )
2017
25
A Rare Case of Biphasic Malignant Peritoneal Mesothelioma with Refractory Ascites. ( 28381756 )
2017
26
Unusual presentation of a late-onset recurrence of malignant peritoneal mesothelioma. ( 28264807 )
2017
27
Rapamycin Treatment for Benign Multicystic Peritoneal Mesothelioma: A Rare Disease with a Difficult Management. ( 28579603 )
2017
28
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% ofA Malignant Peritoneal Mesotheliomas. ( 28034829 )
2017
29
PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma. ( 28877056 )
2017
30
A case of malignant peritoneal mesothelioma suggesting the utility of combining double-contrast radiography and endoscopy with computed tomography for diagnosis. ( 28646342 )
2017
31
Diagnostic Dilemma: Primary Peritoneal Mesothelioma With Para-Occupational Asbestos Exposure. ( 29244982 )
2017
32
Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre. ( 28830230 )
2017
33
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. ( 28594258 )
2017
34
miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells. ( 28716051 )
2017
35
Current management strategies for peritoneal mesothelioma. ( 28664790 )
2017
36
Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. ( 28540826 )
2017
37
Diffuse peritoneal mesothelioma: A case series of 62 patients including paraoccupational exposures to chrysotile asbestos. ( 28940402 )
2017
38
Peritoneal Mesothelioma with Residential Asbestos Exposure. Report of a Case with Long Survival (Seventeen Years) Analyzed by Cgh-Array. ( 28829357 )
2017
39
Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. ( 28849389 )
2017
40
Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma with Cytoreduction and Heated Intraperitoneal Chemotherapy. ( 29027138 )
2017
41
Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. ( 27813512 )
2016
42
Metachronous Uterine Endometrioid Adenocarcinoma and Peritoneal Mesothelioma in Lynch Syndrome: A Case Report. ( 27903930 )
2016
43
A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma. ( 27187383 )
2016
44
Diffuse malignant peritoneal mesothelioma presenting with psammomatous calcification on a cervical smear: A case report. ( 27773157 )
2016
45
Benign Cystic Peritoneal Mesothelioma Revealed by Small Bowel Obstruction. ( 27066288 )
2016
46
A Case of Encapsulating Peritoneal Sclerosis Complicated by Malignant Peritoneal Mesothelioma. ( 27628605 )
2016
47
The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma. ( 27858567 )
2016
48
Symptoms, signs and radiologic findings in patients having reoperative surgery for malignant peritoneal mesothelioma. ( 27612411 )
2016
49
Benign Multicystic Peritoneal Mesothelioma: AIRP Best Cases in Radiologic-Pathologic Correlation. ( 26963453 )
2016
50
CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. ( 26810896 )
2016

Variations for Peritoneal Mesothelioma

Expression for Peritoneal Mesothelioma

Search GEO for disease gene expression data for Peritoneal Mesothelioma.

Pathways for Peritoneal Mesothelioma

GO Terms for Peritoneal Mesothelioma

Biological processes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.56 CDKN2A EGFR ESR1 WT1
2 cellular response to estradiol stimulus GO:0071392 9.32 EGFR ESR1
3 negative regulation of cell-matrix adhesion GO:0001953 9.16 CDKN2A NF2
4 positive regulation of transcription by RNA polymerase II GO:0045944 9.1 CDKN2A EGFR ESR1 MET PGR WT1
5 regulation of toll-like receptor signaling pathway GO:0034121 8.96 BIRC3 ESR1

Molecular functions related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.85 BIRC3 CDKN2A EGFR ESR1 MET MUC1
2 steroid binding GO:0005496 8.96 ESR1 PGR
3 nitric-oxide synthase regulator activity GO:0030235 8.62 EGFR ESR1

Sources for Peritoneal Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....